TESTOSTERONE ENANTHATE INJECTION, USP SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

TESTOSTERONE ENANTHATE

Prieinama:

HIKMA CANADA LIMITED

ATC kodas:

G03BA03

INN (Tarptautinis Pavadinimas):

TESTOSTERONE

Dozė:

200MG

Vaisto forma:

SOLUTION

Sudėtis:

TESTOSTERONE ENANTHATE 200MG

Vartojimo būdas:

INTRAMUSCULAR

Vienetai pakuotėje:

15G/50G

Recepto tipas:

Schedule G (CDSA IV)

Produkto santrauka:

Active ingredient group (AIG) number: 0106403001; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2023-03-17

Prekės savybės

_Testosterone Enanthate Injection, USP _
_Page 1 of 17 _
PRESCRIBING INFORMATION
TESTOSTERONE ENANTHATE INJECTION, USP
Solution for Injection,
200 mg / mL
Androgens
Hikma Canada Limited
5995 Avebury Road, Suite 804
Mississauga, ON
L5R 3P9, Canada
Date of Preparation:
March 17, 2023
Submission Control No: 264978
C
_Testosterone Enanthate Injection, USP _
_Page 2 of 17 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
......................................................................................................
3
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE
REACTIONS
........................................................................................................
7
DOSAGE AND ADMINISTRATION
...................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
11
STORAGE AND STABILITY
...............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 13
PART II: SCIENTIFIC INFORMATION
..................................................................................
14
PHARMACEUTICAL
INFORMATION
................................................................................
14
CLINICAL TRIALS
.............................................................................................................
14
PART III: CONSUMER
INFORMATION................................................................................
16
_Testosterone Enanthate Injection, USP _
_Page 3